P1339 Molecular characterisation of carbapenem-resistant Acinetobacter baumannii isolated in two Turkish medical centres in 2006: report from the SENTRY Antimicrobial Surveillance Program

2007 ◽  
Vol 29 ◽  
pp. S370-S371
Author(s):  
L. Deshpande ◽  
H. Sader ◽  
D. Gur ◽  
V. Korten ◽  
G. Soyletir ◽  
...  
Keyword(s):  
Acinetobacter Baumannii ◽  
Surveillance Program ◽  
Molecular Characterisation ◽  
Carbapenem Resistant ◽  
Antimicrobial Surveillance

scholarly journals Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites

2008 ◽  
Vol 57 (12) ◽  
pp. 1529-1532 ◽  
Author(s):  
Deniz Gur ◽  
Volken Korten ◽  
Serhat Unal ◽  
Lalitagauri M. Deshpande ◽  
Mariana Castanheira
Keyword(s):  
Acinetobacter Baumannii ◽  
Antimicrobial Agents ◽  
Carbapenem Resistance ◽  
Surveillance Program ◽  
Carbapenem Resistant ◽  
Medical Institutions ◽  
Antimicrobial Surveillance ◽  
Resistant Strains ◽  
Resistance Rates ◽  
Encoding Genes

A significant increase in carbapenem-resistance rates among Acinetobacter baumannii isolates collected in two Turkish medical centres was detected in the 2000–2006 period (20–60 %) by the SENTRY Antimicrobial Surveillance Program. Carbapenem-resistant strains from 2006 were evaluated for the presence of encoding genes and epidemic clonality. OXA-58-like and OXA-23-like carbapenemase-producing strains were detected in both medical institutions. Seventeen out of 18 strains from Ankara were positive for bla OXA-58 primers and belonged to the same clone, whilst 26 isolates (25 from Istanbul and one from Ankara) harboured bla OXA-23-like genes and showed identical or similar PFGE patterns. Isolates producing OXA-23-like carbapenemases were more resistant than OXA-58-like carbapenemase producers to non-carbapenem antimicrobial agents. Carbapenem resistance in these institutions was observed to be largely driven by the dissemination of clones producing OXA-type carbapenemases.

scholarly journals Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010)

2013 ◽  
Vol 57 (7) ◽  
pp. 3012-3020 ◽  
Author(s):  
Mariana Castanheira ◽  
Sarah E. Farrell ◽  
Lalitagauri M. Deshpande ◽  
Rodrigo E. Mendes ◽  
Ronald N. Jones
Keyword(s):  
New York ◽  
New York City ◽  
Surveillance Program ◽  
Content Type ◽  
Carbapenem Resistant ◽  
Antimicrobial Surveillance ◽  
Genes Encoding ◽  
Resistant Strains ◽  
User Friendly ◽  
Encoding Genes

ABSTRACTEnterobacteriaceaebacteremia isolates (n= 195; 6.4% overall) collected from 26 U.S. hospitals located in 20 states were screened for various β-lactamase classes. A total of 175 isolates carried one to eight acquired β-lactamase genes of 44 types that were detected in 55 combinations. Eighty-five (43.6%) strains carriedblaCTX-M, andblaCTX-M-15was the most prevalent (33.8%). Genes encoding OXA-1/30 (often associated withblaCTX-M-15), CMY-2, SHV extended-spectrum β-lactamase (ESBLs), and TEM-1 were also prevalent. Among 33 carbapenem-resistant strains, 28 carriedblaKPC-2orblaKPC-3(17 and 11 strains, respectively), and those were recovered mostly in the New York City area (16 strains) and Houston, TX (9 strains). Fourteen new SHV variants were identified amongKlebsiella pneumoniaeisolates carrying one or multiple SHV alleles, three carrying G238S and/or E240K amino acid alterations that confer ESBL activity. Only two of eightK. oxytocaisolates carried acquired β-lactamases, but most had mutations on theblaOXYpromoter region, and three new OXY-encoding genes were characterized. Concordance between a commercial nucleic acid-based microarray (Check-MDR CT101) and reference methods was noted for 105/109 (97.2%) strains. Thirty-two strains having genes that are not targeted by the commercial system were detected (OXA ESBLs, PER, PSE, or intrinsic genes). Overall, a great variety of enzymes were observed, with numerous strains carrying multiple genes. Rates of CTX-M-producing strains appear to be increasing in U.S. hospitals (26.6% in 2007 to 43.8% for 2010) participating in the SENTRY Program. Furthermore, the Check-Points system seems to be a reliable, robust, and user-friendly assay for detection of enzyme-mediated resistance.

scholarly journals Susceptibility to Imipenem/Relebactam of Pseudomonas Aeruginosa and Acinetobacter Baumannii Isolates From Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 To 2018

2021 ◽  
Author(s):  
Hui Zhang ◽  
Peiyao Jia ◽  
Ying Zhu ◽  
Ge Zhang ◽  
Jingjia Zhang ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Urinary Tract ◽  
Acinetobacter Baumannii ◽  
Urinary Tract Infections ◽  
Surveillance Program ◽  
College Hospital ◽  
Medical College ◽  
Carbapenem Resistant ◽  
Tract Infections ◽  
Abdominal Infections

Abstract Background In recent years, less options are available for treating carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa. The present study investigatesthe susceptibility rates to imipenem/relebactamfor the treatment of intra-abdominal infections (IAIs), respiratory tract infections (RTIs) and urinary tract infections (UTIs) caused by A. baumannii and P. aeruginosain China. Methods 1,886 P. aeruginosa and 1,889 A.baumanniiisolates were collected in 21 centers (7 regions) as part of the global SMART surveillance program between 2015 and 2018. Antimicrobial susceptibility testing was performed according tothe Clinical and Laboratory Standards Institute (CLSI) recommendations using the broth microdilution methodology in the Peking Union Medical College Hospital. Results Rates of imipenem-non-susceptibilities of P. aeruginosa and A. baumanniiisolates were 44.3% and 79.0%, whereas the multidrug-resistance (MDR) rateswere 44.3% and 81.9%, respectively.For P. aeruginosa, susceptibility rates to imipenem/relebactamwere 84.2% at aCLSI breakpoint of ≤ 2 mg/L compared to 55.7% for imipenem. The MIC90 of imipenem/relebactam(8 mg/L) was one fourth of that of imipenem (32 mg/L).The susceptibilities of imipenem-non-susceptible and MDRP.aeruginosastrains were similarly restored by imipenem/relebactam in non-ICU and ICU wards.The susceptiblity rate of A. baumannii isolates to imipenem was 21.0% and to imipenem/relebactam 22.2%. Conclusions Imipenem/relebactam provides a therapy option for infections caused by MDRor imipenem-non-susceptible P. aeruginosa infections in China.

scholarly journals Early Dissemination of NDM-1- and OXA-181-ProducingEnterobacteriaceaein Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007

2010 ◽  
Vol 55 (3) ◽  
pp. 1274-1278 ◽  
Author(s):  
Mariana Castanheira ◽  
Lalitagauri M. Deshpande ◽  
Dilip Mathai ◽  
Jan M. Bell ◽  
Ronald N. Jones ◽  
...  
Keyword(s):  
Gel Electrophoresis ◽  
Enterobacter Cloacae ◽  
Pulsed Field Gel Electrophoresis ◽  
Health Care Facilities ◽  
Surveillance Program ◽  
Gene Encoding ◽  
Indian Health ◽  
Carbapenem Resistant ◽  
Antimicrobial Surveillance ◽  
Care Facilities

ABSTRACTAmong 39 carbapenem-resistantEnterobacteriaceae(2.7% overall;Escherichia coli,Enterobacter cloacae, andKlebsiella pneumoniaestrains) isolated in 2006 and 2007 in India, 15 strains carriedblaNDM-1and 10 harbored a gene encoding a variant of the carbapenemase OXA-48, namedblaOXA-181. OneE. cloacaestrain harboredblaVIM-6, and oneK. pneumoniaestrain carryingblaOXA-181also possessedblaVIM-5. Multiple pulsed-field gel electrophoresis patterns and clonal dissemination within and among sites were observed. Isolates producing NDM-1 were disseminated in Indian health care facilities as early as 2006.

Decreased carO gene expression and OXA-type carbapenemases among extensively drug-resistant Acinetobacter baumannii strains isolated from burn patients in Tehran, Iran

2020 ◽  
Author(s):  
Elham Abbasi ◽  
Hossein Goudarzi ◽  
Ali Hashemi ◽  
Alireza Salimi Chirani ◽  
Abdollah Ardebili ◽  
...  
Keyword(s):  
Gene Expression ◽  
Acinetobacter Baumannii ◽  
High Rate ◽  
Burn Patients ◽  
Drug Resistant ◽  
Disc Diffusion ◽  
Carbapenem Resistant ◽  
Extensively Drug Resistant ◽  
Sds Page ◽  
Extensively Drug Resistance

AbstractA major challenge in the treatment of infections has been the rise of extensively drug resistance (XDR) and multidrug resistance (MDR) in Acinetobacter baumannii. The goals of this study were to determine the pattern of antimicrobial susceptibility, blaOXA and carO genes among burn-isolated A. baumannii strains. In this study, 100 A. baumannii strains were isolated from burn patients and their susceptibilities to different antibiotics were determined using disc diffusion testing and broth microdilution. Presence of carO gene and OXA-type carbapenemase genes was tested by PCR and sequencing. SDS-PAGE was done to survey CarO porin and the expression level of carO gene was evaluated by Real-Time PCR. A high rate of resistance to meropenem (98%), imipenem (98%) and doripenem (98%) was detected. All tested A. baumannii strains were susceptible to colistin. The results indicated that 84.9% were XDR and 97.9% of strains were MDR. In addition, all strains bore blaOXA-51 like and blaOXA-23 like and carO genes. Nonetheless, blaOXA-58 like and blaOXA-24 like genes were harbored by 0 percent and 76 percent of strains, respectively. The relative expression levels of the carO gene ranged from 0.06 to 35.01 fold lower than that of carbapenem-susceptible A. baumannii ATCC19606 and SDS – PAGE analysis of the outer membrane protein showed that all 100 isolates produced CarO. The results of current study revealed prevalence of blaOXA genes and changes in carO gene expression in carbapenem resistant A.baumannii.

PREVALENCE OF CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII (CRAB) IN MEDICAL AND SURGICAL INTENSIVE CARE UNITS (ICUS) OF JPMC, KARACHI

2019 ◽  
Author(s):  
Rabia Arshad
Keyword(s):  
Intensive Care ◽  
Antimicrobial Resistance ◽  
Acinetobacter Baumannii ◽  
Intensive Care Units ◽  
Carbapenem Resistance ◽  
Chronic Obstructive ◽  
Surgical Intensive Care ◽  
Carbapenem Resistant ◽  
Number Of Patients ◽  
Increased Risk

Background: Antimicrobial resistance is one of the research priorities of health organizations due to increased risk of morbidity and mortality. Outbreaks of nosocomial infections caused by carbapenem-resistant Acinetobacter Baumannii (CRAB) strains are at rise worldwide. Antimicrobial resistance to carbapenems reduces clinical therapeutic choices and frequently led to treatment failure. The aim of our study was to determine the prevalence of carbapenem resistance in A. baumannii isolated from patients in intensive care units (ICUs). Methods: This cross-sectional study was carried out in the Department of Microbiology, Basic Medical Sciences Institute (BMSI), Jinnah Postgraduate Medical Centre (JPMC), Karachi, from December 2016 to November 2017. Total 63 non-repetitive A. baumannii were collected from the patients’ specimens, admitted to medical and surgical ICUs and wards of JPMC, Karachi. The bacterial isolates were processed according to standard microbiological procedures to observe for carbapenem resistance. SPSS 21 was used for data analysis. Results: Out of the 63 patients, 40 (63.5%) were male. The age of the patient ranged from 15-85 year, with average of 43 year. 34.9% patients had been hospitalized for 3 days. Chronic obstructive pulmonary disease was present in highest number with average of 58.7% for morbidity. Number of patients on mechanical ventilation was highest (65.1%). All isolates were susceptible to colistin. The resistance to ampicillin-sulbactam, ceftazidime, ciprofloxacin, amikacin, piperacillin- tazobactam and meropenem was 82.5%, 81%, 100%, 87.3%, 82.5% and 82% respectively. Out of 82% CRAB, 77% were obtained from ICUs. Conclusion: This study has revealed the high rate of carbapenem resistance in A. baumannii isolates in ICUs thus leaving behind limited therapeutic options.

Sign in / Sign up

Export Citation Format

Share Document